Page 3 - Quantum Genomic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat ( (2) hypertension. This new study is part of firibastat's Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treat...

Share: Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece PARIS and NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) --   Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusiv...

QUANTUM GENOMICS: Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today ann...